We reply within one business dayGet my quote
Pancreatic cancer (pancreatic adenocarcinoma): US-approved treatments and how Gulf families can access them
A plain guide for families in the Gulf, checked against US FDA labels, Gulf drug registers and published medical research.
Reviewed by the Reserve Meds clinical operations team on 17 October 2026.
Pancreatic cancer: the short answer
The US FDA has approved two medicines on this page for pancreatic cancer, each for specific patients. Two of them are on at least one Gulf register we checked, so ask your hospital about local supply first. Otherwise the hospital can request a named-patient import. Reserve Meds is a digital health company. We do not diagnose or prescribe.
- US FDA-approved medicines on this page: Rasonque and Onivyde.
- Gulf registration (checked 17 October 2026): see each medicine below.
- Legal route: Local supply where listed; otherwise a named-patient import request filed by the treating hospital.
- Price: Quote on request.
What is pancreatic cancer?
The pancreas is a gland behind the stomach that makes digestive juices and hormones that control blood sugar. Pancreatic cancer usually begins in the cells that make the digestive juices.[1]
It is hard to catch early because it often causes no symptoms at first. Later symptoms include yellowing of the skin and eyes, pain in the abdomen and back, weight loss and fatigue. Risk factors include smoking, long-term diabetes, chronic pancreatitis and some inherited disorders.[1]
Because it is often found late and spreads quickly, pancreatic cancer can be hard to treat. Options include surgery, radiation, chemotherapy and targeted therapy. In the US, a RAS inhibitor tablet was approved in 2026 for previously treated metastatic pancreatic adenocarcinoma.[1, 2]
Pancreatic cancer in the Gulf
Using 16 annual cancer registry reports from 2005 to 2020, researchers found that pancreatic cancer incidence in Saudi Arabia, though lower than global rates, increased steadily, mostly affecting people aged 50 and older, with higher rates in men.[3]
US FDA-approved medicines for pancreatic cancer
Each medicine below is approved in the US for a specific group of patients. The wording summarizes the current US label. Your specialist decides whether any of them is right for the patient.
- Rasonque (daraxonrasib)
FDA-approved for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multi-drug systemic therapy. It is a tablet.[2]
Gulf registers: Saudi Arabia: not found by brand name in the SFDA drugs list. Abu Dhabi: has an active code in the Abu Dhabi DoH drug code list. Checked 17 October 2026. UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register.[4, 5]
Country guides: Saudi Arabia, UAE, Kuwait, Qatar - Onivyde (irinotecan hydrochloride)
FDA-approved for adults with metastatic pancreatic adenocarcinoma, first-line in combination with oxaliplatin, fluorouracil and leucovorin, and after gemcitabine-based therapy with fluorouracil and leucovorin. It is given by intravenous infusion.[6]
Gulf registers: Saudi Arabia: listed in the SFDA drugs list. Abu Dhabi: has an active code in the Abu Dhabi DoH drug code list. Checked 17 October 2026. UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register.[4, 5]
How families in the Gulf can access these medicines
If the medicine is listed in your country. Ask your specialist and the hospital pharmacy about local supply first. A listing does not mean every hospital stocks the medicine, and another brand of the same medicine may also be registered, but local supply is usually the fastest route and you may not need us.
If it is not registered. The usual legal route is a named-patient request: the treating hospital, on your specialist's written request, asks the national regulator for permission to import the medicine for one patient, using the US FDA approval as the reference. In Saudi Arabia the SFDA Special Access Program guidance covers these requests; in Bahrain, NHRA Circular 41 of 2020 sets the procedure. Other Gulf countries have their own procedures, which the hospital pharmacy confirms.[7, 8] Once approval is in place, Reserve Meds arranges supply through a US-licensed pharmaceutical wholesale partner to the hospital pharmacy.
Who does what
- Your treating specialist decides whether a medicine is right for the patient and writes the letter.
- The hospital checks local supply, files any import request, and gives the treatment safely.
- The national regulator decides whether to approve the import of a medicine that is not registered.
- The manufacturer decides where its medicine can be supplied, especially for cell and gene therapies.
- Reserve Meds helps organize records, coordinates US supply through our wholesale partner, shipping and updates to your family. We do not give medical advice.
Documents you will usually need
- A letter from the treating specialist with the diagnosis, past treatments and why the medicine is being considered
- Reports that confirm the diagnosis, such as laboratory, genetic, imaging or pathology results, translated into English where needed
- Recent clinic notes and a list of current medicines
- For a hospital import request: the prescription, the hospital's request form and the written consent of the patient or guardian
- Proof of the US FDA approval and the US prescribing information (we can supply these)
We give you a written timeline estimate once we see the hospital file. The regulator, the treatment center and the manufacturer set their own timelines.
What treatment costs
Quote on request. Your total cost depends on the medicine, the dose, shipping, import steps and coordination. Your coordination fee is quoted in writing for your case before you commit. No hidden charges.
How Reserve Meds helps
Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We help your doctor and hospital prepare the file, arrange US supply and temperature-controlled shipping once approval is in place, and keep your family updated. We coordinate access to FDA-approved medicines only. Investigational medicines are only available through a manufacturer's expanded-access program requested by the treating physician; we can explain that route, but we do not supply them.
Ask us about treatment for pancreatic cancer
Tell us the medicine, your country and a WhatsApp or phone number. We reply within one business day. On WhatsApp we usually reply the same day.
Frequently asked questions
Is there an FDA-approved treatment for pancreatic cancer?
Yes. The medicines on this page have US FDA approval for specific groups of patients: Rasonque and Onivyde. The exact conditions are in each US label and are summarized above. Your specialist decides whether any of them fits.
Is Rasonque available in Saudi Arabia or the UAE?
Saudi Arabia: not found by brand name in the SFDA drugs list. Abu Dhabi: has an active code in the Abu Dhabi DoH drug code list. Checked 17 October 2026. UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register. A listing in Abu Dhabi does not show federal UAE status.
How can a family in the Gulf get Rasonque?
Ask the treating hospital about local supply first. If it is not available, the hospital can file a named-patient import request with the national regulator on your specialist's written request. Once approved, we arrange US supply to the hospital pharmacy.
How much does treatment cost?
Quote on request. Your total cost, including the medicine, shipping, import steps and coordination, is quoted in writing for your case before you commit. No hidden charges.
Why is pancreatic cancer often found late?
MedlinePlus explains that it usually causes no early symptoms and the pancreas is hidden behind other organs, so doctors cannot see or feel tumors during routine exams.
Is Rasonque available in the Gulf?
Check the register line under Rasonque above. We also publish country access guides for this medicine where they exist.
Sources for the last two answers: [1] [2]
Sources
Checked on 17 October 2026. Labels, registers and regulator rules change. Your hospital pharmacy confirms the current position before filing.
- MedlinePlus (US National Library of Medicine): Pancreatic Cancer
- DailyMed (US National Library of Medicine): Rasonque (daraxonrasib) US prescribing information, version published 31 August 2026
- Elwali et al. Pancreatic cancer in Saudi Arabia (2005-2020): increasing trend. BMC Cancer 2024 (PubMed 38811942)
- SFDA: Drugs List, public register (all 9,173 entries checked by brand name on 17 October 2026)
- Department of Health Abu Dhabi: drug code list Drugs.xlsx (release 26 September 2026, effective 2 October 2026)
- DailyMed (US National Library of Medicine): Onivyde (irinotecan hydrochloride) US prescribing information, version published 5 March 2025
- SFDA: Special Access Program (SAP) guidance, version 1.0
- NHRA Bahrain: Circular No. (41) of 2020, procedures for importing non-registered medicines and pharmaceutical products
Related
- Ovarian cancer
- Non-small cell lung cancer
- Named-patient access in the Gulf, explained
- Answers to common access questions
- Cross-border disclosures
- اقرأ هذه الصفحة بالعربية
- यह पृष्ठ हिंदी में पढ़ें
- یہ صفحہ اردو میں پڑھیں
This page is general health information, not medical advice. It does not replace a consultation with your doctor.